Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Meta-Analysis
. 2020 Mar;37(3):175-185.
doi: 10.1007/s40266-019-00736-y.

The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis

Affiliations
Meta-Analysis

The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis

Zhen Zhou et al. Drugs Aging. .

Abstract

Purpose: The use of statins in the primary prevention of cardiovascular disease (CVD) is increasing in older adults. Nonetheless, good clinical evidence for the safety and tolerability of statins in this population is limited.

Objective: We aimed to evaluate the safety and tolerability of statins in older adults without overt CVD, focusing on statin-related muscle symptoms.

Methods: Double-blinded randomised controlled trials (RCTs) of statins published before January 2012 were identified from a Cochrane review updated to 2012. Trials published between January 2012 and July 2018 were identified through the CENTRAL, MEDLINE and EMBASE databases. Eligible trials were limited to those including individuals aged ≥ 65 years without overt CVD, who were followed for at least 1 year. Trials had to have reported at least one of the outcomes of interest. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects models.

Results: We identified 11 trials, including 18,192 participants (mean age 73.7 years; 43% females). Compared with placebo, statins neither increased the risks of muscle-related symptoms (RR 1.01; 95% CI 0.90-1.12), total adverse events (AEs) and serious AEs nor led to more total permanent treatment discontinuations and discontinuations due to AEs or specifically due to muscle-related symptoms. No evidence of heterogeneity was observed in any of these outcomes.

Conclusions: This meta-analysis of RCTs found no excess incidence of muscle-related symptoms, total AEs, serious AEs and treatment discontinuations attributable to statin treatment compared with placebo among older adults without CVD.

Similar articles

See all similar articles

References

    1. Br J Clin Pharmacol. 2015 Sep;80(3):363-71 - PubMed

References

    1. Curr Rheumatol Rep. 2010 Jun;12(3):213-20 - PubMed

References

    1. Circulation. 2004 Nov 2;110(18):2809-16 - PubMed

References

    1. Ann Intern Med. 2010 Apr 20;152(8):488-96, W174 - PubMed

References

    1. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816 - PubMed

References

    1. Lancet. 2017 Jun 24;389(10088):2473-2481 - PubMed

References

    1. Diabetes Care. 2013 Aug;36 Suppl 2:S325-30 - PubMed

References

    1. Br J Clin Pharmacol. 2019 Jan;85(1):227-235 - PubMed

References

    1. Lancet. 2004 Aug 21-27;364(9435):685-96 - PubMed

References

    1. BMJ. 2009 Jul 21;339:b2700 - PubMed

References

    1. Am J Geriatr Cardiol. 2003 Jul-Aug;12(4):225-31 - PubMed

References

    1. N Engl J Med. 2016 May 26;374(21):2032-43 - PubMed

References

    1. JAMA. 2007 Mar 28;297(12):1344-53 - PubMed

References

    1. N Engl J Med. 2008 Nov 20;359(21):2195-207 - PubMed

References

    1. J Am Coll Cardiol. 2016 May 24;67(20):2395-2410 - PubMed

References

    1. N Engl J Med. 2016 May 26;374(21):2021-31 - PubMed

References

    1. Circulation. 1994 Oct;90(4):1679-87 - PubMed

References

    1. JAMA. 2016 Nov 15;316(19):1971-1972 - PubMed

References

    1. Drugs Aging. 2019 Aug;36(8):687-699 - PubMed

References

    1. J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7 - PubMed

References

    1. J Am Coll Cardiol. 2018 Jan 2;71(1):85-94 - PubMed

References

    1. Expert Opin Drug Saf. 2005 May;4(3):389-97 - PubMed

References

    1. J Hypertens. 2011 Mar;29(3):592-9 - PubMed

References

    1. Cardiovasc Drugs Ther. 2018 Jun;32(3):265-272 - PubMed

References

    1. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed

References

    1. Eur Heart J. 2015 May 1;36(17):1012-22 - PubMed

References

    1. Ann Intern Med. 2013 Apr 2;158(7):526-34 - PubMed

References

    1. Lancet. 2016 Nov 19;388(10059):2532-2561 - PubMed

References

    1. Lancet. 2002 Nov 23;360(9346):1623-30 - PubMed

References

    1. Lancet. 2003 Apr 5;361(9364):1149-58 - PubMed

References

    1. BMC Clin Pharmacol. 2009 Mar 31;9:6 - PubMed

References

    1. Medicine (Baltimore). 2016 Sep;95(39):e4950 - PubMed

References

    1. Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7): - PubMed

References

    1. JAMA Intern Med. 2017 Jul 1;177(7):966 - PubMed

References

    1. JAMA Cardiol. 2017 Jan 1;2(1):56-65 - PubMed

References

    1. BMJ Open. 2017 Sep 27;7(9):e017587 - PubMed

References

    1. JAMA. 2002 Feb 6;287(5):622-7 - PubMed

References

    1. Ann Intern Med. 2002 Oct 1;137(7):617-8 - PubMed

References

    1. Stat Med. 2004 Jun 15;23(11):1663-82 - PubMed

References

    1. Hypertension. 1996 Oct;28(4):647-51 - PubMed

References

    1. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209 - PubMed

References

    1. JAMA. 1998 May 27;279(20):1615-22 - PubMed

References

    1. J Clin Epidemiol. 2011 Apr;64(4):383-94 - PubMed

References

    1. Drugs Aging. 2015 Aug;32(8):649-61 - PubMed

References

    1. Expert Opin Drug Saf. 2018 Jan;17(1):25-37 - PubMed

References

    1. Diabetes Care. 2006 Jul;29(7):1478-85 - PubMed

References

    1. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed

MeSH terms

Substances

LinkOut - more resources

Feedback